Quality of life and burden of disease in a Mexican population with inflammatory bowel disease: an analysis of the RISE-MX trial
Moderate-to-severe activity of disease was associated with a substantial impact on QOL, work productivity, and medical costs in Mexican patients with IBD. Total costs were higher for patients with CD than for patients with UC.
Authors
- R.M. Miranda-Cordero
- Mauricio Mijaíl Rodríguez-Mendoza
- Francisco Bosques‐Padilla (ORCID: https://orcid.org/0000-0002-9795-7209)
- Manuel Martínez-Vazquez (ORCID: https://orcid.org/0000-0002-1591-6877)
- Jesús K. Yamamoto‐Furusho (ORCID: https://orcid.org/0000-0002-5247-5812)
- Cristian Barajas-Maldonado
Institutions
- Universidad Autónoma de Nuevo León (MX)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- Instituto de Salud del Estado de México (MX)
- Takeda (Japan) (JP)
- Tecnológico de Monterrey (MX)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1177/17562848251318032
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82